MEP43808A - Polymer conjugates of mutated neublastin - Google Patents

Polymer conjugates of mutated neublastin

Info

Publication number: MEP43808A
Authority: ME; Montenegro
Prior art keywords: polymer conjugates; mutated neublastin; neublastin; polymer; prolonged
Prior art date: 2003-01-31

Application number

MEP-438/08A

Other languages

Bosnian (bs)

English (en)

Croatian (hr)

Inventor

Dinah Wen-Yee Sah

R Blake Pepinsky

Paula Ann Boriack-Sjodin

Stephan S Miller

Anthony Rossomando

Laura Silvian

Original Assignee

Biogen Idec Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-31

Filing date

2004-02-02

Publication date

2011-02-10

2003-01-31 Priority claimed from US10/356,264 external-priority patent/US7442370B2/en

2004-02-02 Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc

2011-02-10 Publication of MEP43808A publication Critical patent/MEP43808A/xx

Links

102100026376 Artemin Human genes 0.000 title abstract 3
101000785776 Homo sapiens Artemin Proteins 0.000 title abstract 2
229920000642 polymer Polymers 0.000 title abstract 2
239000000539 dimer Substances 0.000 abstract 2
230000002035 prolonged effect Effects 0.000 abstract 2
230000004071 biological effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Virology (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Addiction (AREA)
Psychiatry (AREA)
Psychology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)

MEP-438/08A 2003-01-31 2004-02-02 Polymer conjugates of mutated neublastin MEP43808A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10/356,264 US7442370B2 (en)	2001-02-01	2003-01-31	Polymer conjugates of mutated neublastin
YU20050585A RS52910B (sr)	2003-01-31	2004-02-02	Polimerni konjugati mutiranog neublastina
PCT/US2004/002763 WO2004069176A2 (en)	2001-02-01	2004-02-02	Polymer conjugates of mutated neublastin

Publications (1)

Publication Number	Publication Date
MEP43808A true MEP43808A (en)	2011-02-10

Family

ID=35006489

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-438/08A MEP43808A (en)	2003-01-31	2004-02-02	Polymer conjugates of mutated neublastin

Country Status (26)

Country	Link
EP (3)	EP1594436B1 (de)
JP (3)	JP4742025B2 (de)
KR (2)	KR101216331B1 (de)
CN (2)	CN101166753A (de)
AT (1)	ATE478891T1 (de)
AU (1)	AU2004209966B9 (de)
BR (1)	BRPI0407170A (de)
CA (1)	CA2514510C (de)
CY (2)	CY1111196T1 (de)
DE (1)	DE602004028801D1 (de)
DK (2)	DK1594436T3 (de)
EA (1)	EA008743B1 (de)
ES (2)	ES2450115T3 (de)
GE (3)	GEP20115137B (de)
IL (2)	IL169945A (de)
IS (1)	IS7938A (de)
ME (1)	MEP43808A (de)
MX (1)	MXPA05008168A (de)
NO (1)	NO20054025L (de)
NZ (2)	NZ581460A (de)
PL (1)	PL383683A1 (de)
PT (2)	PT1594436E (de)
RS (1)	RS52910B (de)
SI (2)	SI2246362T1 (de)
UA (2)	UA91178C2 (de)
ZA (1)	ZA200505707B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA008743B1 (ru) *	2003-01-31	2007-08-31	Байоджен Айдек Ма Инк.	Полимерные конъюгаты мутантного неубластина
CA2577690C (en) *	2004-08-19	2013-08-06	Biogen Idec Ma Inc.	Refolding transforming growth factor beta family proteins
US20140092376A1 (en) *	2012-10-01	2014-04-03	Momentive Performance Materials, Inc.	Container and method for in-line analysis of protein compositions
SG11201906552WA (en) *	2017-01-25	2019-08-27	Tessa Therapeutics Pte Ltd	TGF-ß DECOY RECEPTOR
EP4096920A1 (de) *	2020-01-27	2022-12-07	Silcotek Corp.	Biopharmazeutisches herstellungsverfahren und produkt

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU187037B (en)	1983-04-19	1985-10-28	Tibor Sinko	Rope-stretching device
DE3572982D1 (en)	1984-03-06	1989-10-19	Takeda Chemical Industries Ltd	Chemically modified lymphokine and production thereof
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1990006952A1 (fr)	1988-12-22	1990-06-28	Kirin-Amgen, Inc.	Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5252714A (en)	1990-11-28	1993-10-12	The University Of Alabama In Huntsville	Preparation and use of polyethylene glycol propionaldehyde
CA2580812A1 (en)	1991-06-27	1993-01-07	Bristol-Myers Squibb Company	Ctla4 receptor, fusion proteins containing it and uses thereof
CA2092271C (en)	1993-03-09	2009-10-13	Eddie Reed	Use of g-csf for treating taxol side-effects
US5834029A (en)	1994-07-20	1998-11-10	Cytotherapeutics, Inc.	Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
US5770577A (en) *	1994-11-14	1998-06-23	Amgen Inc.	BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
CN1163509C (zh)	1996-05-08	2004-08-25	拜奥根有限公司	刺激神经和肾生长的RET配体(RetL)
KR100195886B1 (ko)	1996-11-01	1999-06-15	김상조	당뇨병 치료용 의약조성물
ES2297889T3 (es) *	1997-07-14	2008-05-01	Bolder Biotechnology, Inc.	Derivados de hormona de crecimiento y proteinas relacionadas.
US6593133B1 (en) *	1998-07-06	2003-07-15	Nsgene A/S	Neurotrophic factors
US20020055467A1 (en) *	1998-07-06	2002-05-09	Johansen Teit E.	Novel neurotrophic factors
US6284540B1 (en) *	1998-09-29	2001-09-04	Washington University	Artemin, a novel neurotrophic factor
WO2000034475A2 (en) *	1998-12-09	2000-06-15	Amgen Inc.	Grnf4, a gdnf-related neurotrophic factor
NZ526610A (en) *	2000-12-22	2009-08-28	Genentech Inc	New use of artemin, a member of the GDNF ligand family
DK1355936T3 (da)	2001-02-01	2007-10-29	Biogen Idec Inc	Polymerkonjugater af neublastin og fremgangsmåder til anvendelse af samme
CN1525866B (zh) *	2001-03-28	2013-05-29	比奥根艾迪克Ma公司	神经胚活素多肽的治疗作用
EA008743B1 (ru) *	2003-01-31	2007-08-31	Байоджен Айдек Ма Инк.	Полимерные конъюгаты мутантного неубластина
WO2004094592A2 (en) *	2003-04-18	2004-11-04	Biogen Idec Ma Inc.	Polymer-conjugated glycosylated neublastin

2004
- 2004-02-02 EA EA200501212A patent/EA008743B1/ru not_active IP Right Cessation
- 2004-02-02 PL PL383683A patent/PL383683A1/pl unknown
- 2004-02-02 EP EP04707363A patent/EP1594436B1/de not_active Expired - Lifetime
- 2004-02-02 PT PT04707363T patent/PT1594436E/pt unknown
- 2004-02-02 UA UAA200508412A patent/UA91178C2/ru unknown
- 2004-02-02 CA CA2514510A patent/CA2514510C/en not_active Expired - Fee Related
- 2004-02-02 CN CNA200480009133XA patent/CN101166753A/zh active Pending
- 2004-02-02 UA UAA200912089A patent/UA105892C2/uk unknown
- 2004-02-02 KR KR1020057014050A patent/KR101216331B1/ko not_active Expired - Fee Related
- 2004-02-02 DK DK04707363.0T patent/DK1594436T3/da active
- 2004-02-02 GE GEAP200410236A patent/GEP20115137B/en unknown
- 2004-02-02 DK DK10173737.7T patent/DK2246362T3/en active
- 2004-02-02 NZ NZ581460A patent/NZ581460A/en not_active IP Right Cessation
- 2004-02-02 ME MEP-438/08A patent/MEP43808A/xx unknown
- 2004-02-02 EP EP10173737.7A patent/EP2246362B1/de not_active Expired - Lifetime
- 2004-02-02 ES ES10173737.7T patent/ES2450115T3/es not_active Expired - Lifetime
- 2004-02-02 MX MXPA05008168A patent/MXPA05008168A/es active IP Right Grant
- 2004-02-02 SI SI200432136T patent/SI2246362T1/sl unknown
- 2004-02-02 GE GEAP20048957A patent/GEP20084464B/en unknown
- 2004-02-02 EP EP10181704A patent/EP2301960A3/de not_active Withdrawn
- 2004-02-02 AU AU2004209966A patent/AU2004209966B9/en not_active Ceased
- 2004-02-02 SI SI200431548T patent/SI1594436T1/sl unknown
- 2004-02-02 ES ES04707363T patent/ES2351215T3/es not_active Expired - Lifetime
- 2004-02-02 CN CN201110239061.XA patent/CN102367277B/zh not_active Expired - Fee Related
- 2004-02-02 RS YU20050585A patent/RS52910B/sr unknown
- 2004-02-02 KR KR1020127021783A patent/KR101293805B1/ko not_active Expired - Fee Related
- 2004-02-02 GE GEAP200411544A patent/GEP20135982B/en unknown
- 2004-02-02 JP JP2006503213A patent/JP4742025B2/ja not_active Expired - Fee Related
- 2004-02-02 NZ NZ541921A patent/NZ541921A/en not_active IP Right Cessation
- 2004-02-02 BR BRPI0407170-0A patent/BRPI0407170A/pt not_active IP Right Cessation
- 2004-02-02 DE DE602004028801T patent/DE602004028801D1/de not_active Expired - Lifetime
- 2004-02-02 AT AT04707363T patent/ATE478891T1/de active
- 2004-02-02 PT PT101737377T patent/PT2246362E/pt unknown
2005
- 2005-07-12 IS IS7938A patent/IS7938A/is unknown
- 2005-07-15 ZA ZA200505707A patent/ZA200505707B/en unknown
- 2005-07-28 IL IL169945A patent/IL169945A/en not_active IP Right Cessation
- 2005-08-30 NO NO20054025A patent/NO20054025L/no not_active Application Discontinuation
2010
- 2010-03-24 JP JP2010069011A patent/JP2010184924A/ja not_active Withdrawn
- 2010-11-23 CY CY20101101050T patent/CY1111196T1/el unknown
2011
- 2011-01-17 JP JP2011007339A patent/JP2011078434A/ja not_active Withdrawn
2013
- 2013-08-01 IL IL227752A patent/IL227752A0/en unknown
2014
- 2014-03-13 CY CY20141100203T patent/CY1115085T1/el unknown

Also Published As

Publication number	Publication date
JP2007525152A (ja)	2007-09-06
EP2246362A2 (de)	2010-11-03
NO20054025L (no)	2005-10-31
CA2514510C (en)	2013-10-01
EP2301960A2 (de)	2011-03-30
IL169945A (en)	2015-03-31
ES2450115T3 (es)	2014-03-24
EP1594436A2 (de)	2005-11-16
GEP20135982B (en)	2013-12-10
EA200501212A3 (ru)	2006-10-27
GEP20084464B (en)	2008-08-25
ZA200505707B (en)	2007-01-31
IL227752A0 (en)	2013-09-30
KR20120099161A (ko)	2012-09-06
DE602004028801D1 (de)	2010-10-07
EA008743B1 (ru)	2007-08-31
SI2246362T1 (sl)	2014-04-30
AU2004209966B2 (en)	2008-04-17
EP2246362B1 (de)	2013-12-18
AU2004209966B9 (en)	2008-06-26
NZ541921A (en)	2010-01-29
CN102367277A (zh)	2012-03-07
CY1115085T1 (el)	2016-12-14
ATE478891T1 (de)	2010-09-15
EP2246362A3 (de)	2011-02-23
KR101293805B1 (ko)	2013-08-06
JP2010184924A (ja)	2010-08-26
EP1594436A4 (de)	2008-05-28
CA2514510A1 (en)	2004-08-19
IS7938A (is)	2005-07-12
CN102367277B (zh)	2014-04-09
CN101166753A (zh)	2008-04-23
PT1594436E (pt)	2010-11-29
JP4742025B2 (ja)	2011-08-10
HK1085663A1 (en)	2006-09-01
JP2011078434A (ja)	2011-04-21
RS20050585A (sr)	2007-11-15
ES2351215T3 (es)	2011-02-01
UA105892C2 (uk)	2014-07-10
EP2301960A3 (de)	2011-08-03
EP1594436B1 (de)	2010-08-25
DK2246362T3 (en)	2014-03-10
SI1594436T1 (sl)	2011-01-31
KR101216331B1 (ko)	2012-12-28
NO20054025D0 (no)	2005-08-30
PT2246362E (pt)	2014-03-10
UA91178C2 (ru)	2010-07-12
CY1111196T1 (el)	2015-06-11
DK1594436T3 (da)	2010-12-13
MXPA05008168A (es)	2005-10-05
NZ581460A (en)	2010-02-26
AU2004209966A1 (en)	2004-08-19
AU2004209966A2 (en)	2004-08-19
BRPI0407170A (pt)	2006-02-21
RS52910B (sr)	2014-02-28
KR20050099514A (ko)	2005-10-13
EA200501212A2 (ru)	2006-08-25
GEP20115137B (en)	2011-01-10
PL383683A1 (pl)	2008-04-14

Publication	Publication Date	Title
CY1106789T1 (el)	2012-05-23	Γενικος φορεας για στοχευση μοριων σε κυτταρα που εκφραζουν gb3 υποδοχεα
AR072596A1 (es)	2010-09-08	Un complejo proteico que comprende una proteina dimerica y un polimero no peptidico
ATE509634T1 (de)	2011-06-15	Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
BRPI0512286A (pt)	2008-03-18	proteìnas quiméricas inibidoras da angiogênese e o uso
ATE341627T1 (de)	2006-10-15	Als lerk6 bezeichnetes cytokin
MEP43808A (en)	2011-02-10	Polymer conjugates of mutated neublastin
BRPI0408331A (pt)	2006-03-21	conjugado de polipetìdeo fisiologicamente ativo possuindo meia vida útil in vivo prolongada
DK0981618T4 (da)	2011-11-21	Anti-Apo-2-antistof
CY1113353T1 (el)	2016-06-22	Φαρμακοτεχνικη μορφη αντι-τνf-αλφα αντισωματος
CY1106886T1 (el)	2012-09-26	Πολυμερη προϊοντα συζευξης της neublastin και μεθοδοι χρησης αυτων
TR200401793T4 (tr)	2004-08-23	Perindopril tuzu ve bunu içeren farmasötik bileşimler.
ATE433759T1 (de)	2009-07-15	Polymerkonjugiertes glycosiliertes neublastin
BR0108056A (pt)	2003-01-28	Preparados cosméticos com extratos waltheria indica
DE50009240D1 (de)	2005-02-17	Verwendung von Antikörpern zur Vakzinierung gegen Krebs
DE60317565D1 (de)	2007-12-27	Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-liganden
ES2068300T3 (es)	1995-04-16	Metodos y materiales para conseguir resistencia a la inhibicion de la actividad por phea.
EA200401331A1 (ru)	2005-04-28	Фармацевтическая препаративная форма, включающая мелатонин
HRP20080602T3 (hr)	2008-12-31	Amidometil-supstituirani derivati 2-(4-sulfonilamin)-3,4-dihidro-2h-kromen-6, postupci njihovog dobivanja i međuproizvodi, te lijekovi koji sadrže teveze
HRP20041178B1 (hr)	2013-11-22	Muteini placentalnog faktora rasta tipa 1, metode njihove pripreme i primjene
EP1760152A4 (de)	2007-08-08	Verfahren zur dipeptidherstellung
DE50011003D1 (de)	2005-09-29	Haartonikum mit L-Arginin als Wirkstoff
TR200301731U (tr)	2003-12-22	Mobilya
ATE330671T1 (de)	2006-07-15	Verwendung von alkyl 3-(n- alkylacetamino)propionat derivaten als feuchthaltemittel
CY1114475T1 (el)	2016-10-05	Τροποποιημενη ανθρωπινη θυμικη λεμφοποιητινη
BR8202981U (pt)	2003-09-02	Disposição construtiva aplicada à cadeira